Health

Rising drug prices said to strain hospitals

That in turn forces budget cuts

Jim Slosiarek/The Gazette

Drugs associated with outpatient care, which includes emergency room visits and other short-term services, have been the most costly. Outpatient drug spending has increased 28.7 percent per admission, while inpatient spending have grown by 9.6 percent.
Jim Slosiarek/The Gazette Drugs associated with outpatient care, which includes emergency room visits and other short-term services, have been the most costly. Outpatient drug spending has increased 28.7 percent per admission, while inpatient spending have grown by 9.6 percent.
/

Rising costs of prescription drugs have strained hospital budgets and operations, forcing health systems to cut costs by reducing staff, a new study found.

Hospital drug spending increased by 18.5 percent between 2015 and 2017, a rate far exceeding medical inflation for the period, according to a report prepared for three health associations by the research group NORC at the University of Chicago.

Community hospitals spent an average of $555.40 on prescription drugs for each admitted patient in 2017.

“We are in the midst of a prescription drug spending crisis that threatens patient access to care and hospitals’ and health systems’ ability to provide the highest quality of care,” said Rick Pollack, chief executive officer of the American Hospital Association, which commissioned the report along with the Federation of American Hospitals and the American Society of Health-System Pharmacists.

Drugs associated with outpatient care, which includes emergency room visits and other short-term services, were the most costly.

Outpatient drug spending increased 28.7 percent per admission, while inpatient spending grew by 9.6 percent.

Price hikes that affected hospitals were seen across various classes of drugs, including anesthetics, non-oral solutions and chemotherapy.

ARTICLE CONTINUES BELOW ADVERTISEMENT

The main drivers of the increases were high list prices set by drugmakers, coupled with ongoing shortages for critical treatments, according to NORC’s data analysis of more than 4,200 U.S. hospitals.

The report comes as pharmaceutical companies are under increasing pressure from the Trump administration, Congress and insurance companies over rising drug costs.

Drugmakers boosted list prices on hundreds of treatments this month alone.

Earlier this month, President Donald Trump summoned his top health officials to the White House to discuss the increases, while lashing out at drugmakers on Twitter.

Drug shortages are also contributing to rising costs.

As common drugs such as saline solutions and generic injectables are increasingly difficult to obtain, many have shot up in price, straining hospitals that rely on the treatments for daily patient care, according to the study.

However, those drugs often don’t see prices fall to the original level after a new supply floods the market.

“Price increases and drug shortages are the two biggest pain points for hospitals and have been for several years,” said Erin Fox, senior director of pharmacy at University of Utah Health, who monitors drug shortages and assisted with the report.

“Hospitals are still struggling to make do as these issues are ongoing. Some of the shortages highlighted in the report might not be resolved until 2020.”

The number of drugs in short supply in the U.S. has skyrocketed since 2017, when there were 146 shortages, according to the American Society of Health-System Pharmacists.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Thank you for signing up for our e-newsletter!

You should start receiving the e-newsletters within a couple days.

Already, the ASHP has identified 250 active shortages in 2018 — and Fox and her colleagues still ARE counting.

The effects of drug price hikes and shortages have reverberated throughout health systems.

More than nine in 10 hospitals identified alternative therapies to mitigate budget pressures associated with changing drug prices, while one in four hospitals went as far as cutting staff to curb costs, according to the report.

Hospitals also are delaying internal investments and conducting more in-house compounding.

Health systems have urged Congress and the U.S. Food and Drug Administration to act.

In a Jan. 11 letter to FDA Commissioner Scott Gottlieb, who oversees a drug shortage task force, the AHA recommended that manufacturers face more severe drug-shortage disclosure requirements and be fined should they fail to comply.

“Solutions must be worked on to rein in out-of-control drug prices and ease the drug shortages that are putting a strain on patient care,” Pollack said.

Give us feedback

We value your trust and work hard to provide fair, accurate coverage. If you have found an error or omission in our reporting, tell us here.

Or if you have a story idea we should look into? Tell us here.

CONTINUE READING

Give us feedback

We value your trust and work hard to provide fair, accurate coverage. If you have found an error or omission in our reporting, tell us here.

Or if you have a story idea we should look into? Tell us here.